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Therapeutic targeting of Chk1 in NSCLC stem cells
during chemotherapy
M Bartucci1, S Svensson2, P Romania1, R Dattilo1, M Patrizii1, M Signore1, S Navarra1, F Lotti1, M Biffoni1, E Pilozzi3, E Duranti3,
S Martinelli1, C Rinaldo4, A Zeuner1, M Maugeri-Sacca`1, A Eramo1 and R De Maria*,1,2
Cancer stem cell (SC) chemoresistance may be responsible for the poor clinical outcome of non-small-cell lung cancer (NSCLC)
patients. In order to identify the molecular events that contribute to NSCLC chemoresistance, we investigated the DNA damage
response in SCs derived from NSCLC patients. We found that after exposure to chemotherapeutic drugs NSCLC-SCs undergo
cell cycle arrest, thus allowing DNA damage repair and subsequent cell survival. Activation of the DNA damage checkpoint
protein kinase (Chk) 1 was the earliest and most significant event detected in NSCLC-SCs treated with chemotherapy,
independently of their p53 status. In contrast, a weak Chk1 activation was found in differentiated NSCLC cells, corresponding to
an increased sensitivity to chemotherapeutic drugs as compared with their undifferentiated counterparts. The use of Chk1
inhibitors in combination with chemotherapy dramatically reduced NSCLC-SC survival in vitro by inducing premature cell cycle
progression and mitotic catastrophe. Consistently, the co-administration of the Chk1 inhibitor AZD7762 and chemotherapy
abrogated tumor growth in vivo, whereas chemotherapy alone was scarcely effective. Such increased efficacy in the combined
use of Chk1 inhibitors and chemotherapy was associated with a significant reduction of NSCLC-SCs in mouse xenografts. Taken
together, these observations support the clinical evaluation of Chk1 inhibitors in combination with chemotherapy for a more
effective treatment of NSCLC.
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In spite of the large number of clinical trials aimed at improving
patient survival, lung cancer is the most common cause of
cancer-related mortality worldwide.1 Based on histology,
more than 80% of lung tumors are non-small-cell lung cancers
(NSCLCs), whose major subtypes are adenocarcinoma,
squamous and large cell carcinomas.2,3 Recent data indicate
that stem cells (SCs) situated throughout the airways may
initiate cancer formation and be responsible for the failure of
current treatments on lung cancer.4–6 This concept has
changed the view of cancer treatment opening a range of
novel therapeutic interventions to prevent tumor recurrence
and achieve long-term remission and survival of cancer
patients. Cancer SCs (CSCs) are slow-dividing cells that have
an unlimited proliferative potential. Several mechanisms have
been proposed to explain CSC resistance to conventional
therapies, including high expression of anti-apoptotic or
multidrug resistance proteins 7–12 and efficient DNA repair
system.13 Such resistance seems to be responsible for tumor
relapse or recurrence.4 Thus, sensitization of CSCs to
chemotherapy appears as a major goal toward the improve-
ment of the clinical outcome of patients with incurable tumors.
One of the main hallmarks of neoplastic transformation is
deregulation of cell cycle. When defects in cell division are
detected, the DNA damage response prevents phase transi-
tion through the activation of cell cycle checkpoints, which
induce cell cycle arrest allowing repair of damaged DNA.
Critical molecules in the DNA damage machinery after chemo-
therapy or ionizing radiations (IR) are p53 and the checkpoint
protein kinases (Chk) 1 and Chk2. In particular, p53 induces
growth arrest by holding the cell cycle at both the G1/S and
G2/M regulation points,
14,15 whereas Chk1 contributes to DNA
damage repair by affecting S-phase and G2/M phase arrest.
16,17
Unlike Chk2, which is thought to be only an amplifier of
checkpoint responses,18 Chk1 possesses an essential role in
the maintenance of DNA integrity. In the event of cell cycle
alteration due to DNA damage, Chk1 phosphorylates the family
of Cdc25 phosphatases, which in turn inhibit the regulatory
protein Cdc2 by preventing its premature activation.16 As a
consequence, cells are arrested at checkpoints until damaged
DNA has been repaired. Cdc2 activity depends on the interaction
with a co-factor, cyclin B1. Only when dephosphorylated, Cdc2
forms a complex with cyclin B1 and allows dividing cells to enter
mitosis from G2 phase, thus maintaining the highly regulated
temporal order of cell cycle progression.19
Here, we investigated the mechanisms responsible
for NSCLC-SC chemoresistance. We demonstrated that,
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independently of p53 status, Chk1 activation has a major role
in the DNA damage response of NSCLC-SCs and may
represent a key therapeutic target for NSCLC.
Results
NSCLC-SCs proficiently repair chemo-induced DNA
damage. NSCLC-SCs are undifferentiated and highly
clonogenic cells that are largely resistant in vitro and
in vivo to conventional chemotherapy.4,5 We have previ-
ously determined that lung cancer spheres contain a
significant percentage of stem-like cells endowed with the
ability to self-renew.5 By limiting dilution analysis such
number is higher if compared with freshly dissociated tumor
samples and remains stable after serial passages in
secondary and tertiary culture (Supplementary Figure S1A).
To determine the basis of chemoresistance in NSCLC,
we investigated the effects of chemotherapeutic drugs on
primary cultures of NSCLC-SCs derived from five different
NSCLC patients before and after serum-induced differ-
entiation (Supplementary Figure S1B). All five NSCLC-SC
lines were genetically characterized for the presence of
common alterations exhibited by lung tumors (Table 1).
Cisplatin, gemcitabine and paclitaxel were used at doses
comparable with the plasma levels reached in treated lung
cancer patients. Unlike in their differentiated progeny, neither
of the drugs induced remarkable cell death in NSCLC-SCs
even after a long exposure (Figure 1a). Following chemo-
therapy treatment, NSCLC-SCs underwent a transient
growth arrest that lasted until drug removal (Figure 1b).
Accordingly, the analysis of cell cycle profile after drug
treatment in both p53 wild type (wt) and mutated cells
revealed an accumulation of NSCLC-SCs at S and G2 phase
(Figure 1c and Supplementary Figure S2). Specifically, the
number of cells in G2/M increased significantly after cisplatin
and paclitaxel treatment, whereas gemcitabine caused a
significant accumulation in S phase. Cell cycle arrest may
follow DNA damage and checkpoint activation. One of the
earliest modifications of the chromatin structure in the
damage response is phosphorylation of histone H2A.X at
Ser 139 (g-H2A.X).20 Short exposure (6 h) of NSCLC-SCs
to cisplatin, gemcitabine or paclitaxel resulted in a consi-
derable increase in g-H2A.X (Figure 1d). However, the
persistence of g-H2A.X was not detectable or only slightly
evident after 96 h (Figure 1d), suggesting that NSCLC-SCs
are able to efficiently repair the DNA damage induced by
chemotherapy. In contrast, the small fraction of differentiated
cells that survived 96 h treatment displayed a severely
damaged DNA (Supplementary Figure S3A).
NSCLC-SCs resistance to chemotherapy is associated
with rapid and sustained Chk1 activation regardless
their p53 status. Cell cycle checkpoints are controlled by
the ataxia telangiectasia mutated (ATM) and ataxia
telangiectasia and Rad3-related protein (ATR) sensor
kinases,21 which phosphorylate downstream effector
proteins, such as Chk1 and Chk2.22,23 Short treatment (6 h)
of NSCLC-SCs with either cisplatin, gemcitabine or
paclitaxel, promptly induced phosphorylation of ATM
(Figure 2a), followed by a strong activation of Chk1 but
not Chk2 (Figure 2a), which appears phosphorylated at
later time and only after cisplatin and gemcitabine treatment
in both p53 wild type and mutated cells (Supplementary
Figure S3B right and left panel). Unexpectedly, in p53
wt NSCLC-SC # 3, p53 activation was detectable only
as a secondary event in response to DNA damage
(Supplementary Figure S3C). These data indicate that
chemotherapy-induced DNA damage results in cell cycle
arrest mediated mainly by Chk1 and later involving Chk2
and p53. We next compared the activation of Chk1 between
NSCLC-SCs and differentiated progeny in both p53-mutated
and p53-proficient cells. Interestingly, in both cell types, Chk1
phosphorylation in NSCLC-SCs appeared much higher than
in their differentiated counterparts (Figure 2b), suggesting
that NSCLC-SCs can more efficiently counteract DNA
damage through Chk1 and Chk2 activation independently
from their p53 status.
We therefore investigated whether checkpoint abrogation
with the specific Chk1/Chk2 inhibitors SB21807824 and
AZD7762 25 could increase the cytotoxicity of DNA-damaging
agents in NSCLC-SCs. Both inhibitors showed a high efficacy
in abrogating Chk1-mediated phosphorylation of Cdc25
(Figure 2c). Combination of chemotherapeutic drugs with
either of the Chk1 inhibitors prevented DNA repair, as shown
by the persistence of g-H2A.X after 96 h of treatment
(Figure 2d and Supplementary Figure S3D), suggesting that
in the presence of Chk1 inhibitors NSCLC-SCs lose the ability
to repair damaged DNA and may be targeted more efficiently.
Accordingly, while having little activity as single agents, Chk1
inhibitors significantly potentiated the cytotoxic effects of
gemcitabine, cisplatin and paclitaxel (Figure 2e). Differen-
tiated progenies died after long exposure to chemotherapy
independently from the presence of the Chk1 inhibitors (data
not shown), confirming that DNA repair activity is much more
efficient in NSCLC-SCs as compared with differentiated cells.
To generalize our findings beyond the setting of estab-
lished NSCLC-SC cell lines, we evaluated the colony-forming
ability of freshly dissociated NSCLC cells in the presence
of chemotherapy alone or in combination with AZD7762.
We found a marked inhibition of sphere formation by the
Table 1 Mutation status of NSCLC-SCs used in this study
KRAS
exon 1
KRAS
exon 2
p53
exon 5
p53
exon 6
p53
exon 7
p53
exon 8
EGFR
exon 18
EGFR
exon 19
EGFR
exon 21
NSCLC-SC # 1 WT WT WT Tyr220Cys, hom. WT WT WT WT WT
NSCLC-SC # 2 WT WT WT Tyr220Cys, hom. WT WT WT WT WT
NSCLC-SC # 3 WT WT WT WT WT WT WT WT WT
NSCLC-SC # 4 WT WT WT WT Gly245Cys, hom. WT WT WT WT
NSCLC-SC # 5 WT WT WT Tyr220Cys, hom. WT WT WT WT WT
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combination of chemotherapy and the Chk1 inhibitor
(Figure 2f), thus confirming a preferential targeting of the
clonally expanding cells.
Chk1 inhibitors induce mitotic catastrophe through
premature activation of Cdc2/cyclin B1 complex in
NSCLC-SCs. To gain insight into the molecular
mechanisms responsible for increased DNA damage and
cell death with the combination of chemotherapeutic drugs
and Chk1 inhibitors, we analyzed the expression of Cdc2 and
cyclin B1, two cell cycle regulatory proteins known to be
controlled by Chk1. We found that inhibition of Chk1 following
chemotherapy-induced upregulation of Cdc2 activity by
dephosphorylation and decreased expression of cyclin B1
(Figure 3a), probably through nuclear translocation and
subsequent degradation. These events lead to abrogation
of cell cycle arrest and aberrant mitotic entry before the
completion of DNA repair. Cyclin B1 accumulates in the
cytoplasm throughout S and G2 phases and translocates to
the nucleus during prophase.26 We observed that after 48 h
of cisplatin treatment, cyclin B1 was prevalently located in the
cytoplasm of NSCLC-SCs, as a sign of cell cycle arrest. By
contrast, in cells treated with both cisplatin and SB218078,
cyclin B1 translocated from the cytoplasm to the nucleus and
forced cells to proceed through the cell cycle (Figure 3b).
The cytotoxic potential of DNA-damaging agents depends
on their ability to induce growth arrest and activate the cell
death machinery. Cell death can be classified according to
enzymological criteria or morphological appearance in apop-
tosis, necrosis, autophagy or mitotic catastrophe.27,28 The
combination of Chk1 inhibitors and chemotherapeutic drugs
induced the formation of a large number of multinucleated
NSCLC-SCs (Figures 3c and d), suggesting that cells were
dying by mitotic catastrophe.
Treatment with chemotherapeutic drugs and Chk1
inhibitors impairs colony formation of NSCLC-SCs. To
investigate the long-term impact of the treatment with
Figure 1 NSCLC-SCs are resistant to conventional chemotherapeutic drugs and efficiently repair DNA damage. (a) NSCLC-SCs from five different patients and
corresponding differentiated progeny treated with chemotherapeutic drugs for 96 h. Cell viability was measured by CellTiter-Glo assay. The results shown are the mean±S.D.
of three independent experiments.(b) Proliferation of untreated NSCLC-SCs (control) or NSCLC-SCs exposed to chemotherapy for 6 days. Data plotted are the results±S.D.
of three independent experiments performed on four different NSCLC-SC lines.(c) Representative cell cycle profiles of control or treated NSCLC-SCs. (d) g-H2A.X expression
after 6 h and 96 h drugs treatment. b-actin was used as loading control. Lower panels indicate actin-normalized and g-H2A.X levels for each condition. A representative of
three independent experiments is shown. All experiments were performed using 5 mg/ml cisplatin, 50mM gemcitabine and 30 ng/ml paclitaxel. ***P-valueo0.001
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anti-neoplastic drugs in combination with Chk1 inhibitors,
we performed soft agar assays to evaluate differences in
colony-forming abilities. Our results showed that NSCLC-
SCs maintain the ability to form colonies after single
treatment with cisplatin, paclitaxel or Chk1 inhibitors but
not after the combinations of both chemotherapy and
SB218078 or AZD7762 (Figures 4a and b). Together these
results confirm that the combination of chemotherapy with
Chk1 inhibitors impairs survival and clonogenic activity of
NSCLC-SCs.
Chk1 inhibitors potentiate the effect of chemotherapy in
NSCLC-SC-based tumor xenografts. Xenotransplantation
of tumor SCs may provide a solid preclinical model for the
Figure 2 Increased cytotoxicity of chemotherapy by Chk1 inhibitors on NSCLC-SCs. (a) Activation of DNA damage proteins in untreated (control) or 6 h treated
NSCLC-SC # 1 and NSCLC-SC # 3. (b) Western blot analysis for p-Chk1 in NSCLC-SC # 1, NSCLC-SC # 5, NSCLC-SC # 3 and differentiated progenies untreated or treated
with gemcitabine for 12 h. (c) Modulation of phosphorylated Cdc25C (p-Cdc25) in 24-h-treated NSCLC-SC # 3. (d) g-H2A.X expression in NSCLC-SC # 1, NSCLC-SC # 5 and
NSCLC-SC # 3 treated for 96 h as indicated. In each Western blot analysis, the relative densitometric values are normalized over b-tubulin or b-actin. A representative of three
independent experiments is shown. (e) Cell viability of NSCLC-SCs after treatment with chemotherapy alone or in combination with Chk1 inhibitors. Mean±S.D. from four
independent experiments performed on five different NSCLC-SC lines is shown. Cells were exposed to 5 mg/ml cisplatin, 50mM gemcitabine, 30 ng/ml paclitaxel, 20 nM
SB218078 and 5 nM AZD7762, respectively. (f) Colony-forming ability assay on freshly isolated tumor cells. Mean±S.D. of 24 wells/condition obtained by treating and plating
cells from four different NSCLC patients. ***P-valueo0.001
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Figure 3 Chk1 inhibition induces Cdc2 activation and mitotic catastrophe in NSCLC-SCs. (a) NSCLC-SC # 1, NSCLC-SC # 2, NSCLC-SC # 3 and NSCLC-SC
# 4 analyzed for p-Cdc2 and cyclin B1 expression after 96 h of indicated treatments. b-actin was used to assess equal loading. Lower panels indicate actin-normalized protein
level for each condition. A representative of three independent experiments is shown. (b) Representative immunofluorescence staining for cyclin B1 localization in NSCLC-
SCs after 48 h of treatments. Arrowheads indicate cytoplasmic cyclin B1 localization. Acquisition was made with a 40 objective. (c) Representative immunofluorescence of
NSCLC-SCs stained with Phalloidin and DAPI to visualize multinucleated cells. Acquisition was made with a 20 objective. (d) Percentage of multinucleated cells estimated
by counting nuclei in 100 cells on each Phalloidin-DAPI-stained slide. Arrowheads point to multinucleated cells. Mean±S.D. of three independent experiments performed on
four different NSCLC-SC lines is reported. All experiments were performed with 5 mg/ml cisplatin, 50mM gemcitabine, 30 ng/ml paclitaxel, 20 nM SB218078 and 5 nM
AZD7762. ***P-valueo0.001
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development of effective anti-cancer therapies.29 To
evaluate the ability of Chk1 inhibitors to enhance
cytotoxicity of anti-neoplastic agents in lung cancer
treatment in vivo, we assessed the effect of AZD7762 on
human lung carcinoma xenografts generated by
subcutaneous transplantation of NSCLC-SCs into NOD-
SCID mice, which produce a phenocopy of the original
tumor (Figure 5a left and right panel) with a considerably
higher efficiency than bulk tumor cells (Supplementary
Figure S4). Tumors were allowed to grow until they
reached a size of B0.3 cm3. Mice were then treated
intraperitoneally every 3 days for 4 weeks with
chemotherapy alone or in combination with AZD7762,
injected intravenously 8 h after chemotherapy. We
observed that co-treatment of AZD7762 with gemcitabine
or cisplatin significantly affected tumor size (Figure 5b left
and right panel) and weight (Figure 5c left and right panel).
Because after chemotherapy withdrawal tumors often
regrow, a cohort of animals were observed for an extended
period of 3 weeks after the last treatment, for a total of
Figure 4 Chk1 inhibition reduces colony-forming ability of NSCLC-SCs. (a) Representative pictures of NSCLC-SC # 1 (left panel) and NSCLC-SC#3 (right panel) colonies
obtained in soft agar assay under standard growth condition (control) or after treatment with cisplatin (5mg/ml) and paclitaxel (30 ng/ml) alone or in combination
with SB218078 (20 nM) and AZD7762 (5 nM). (b) Average number of colonies/plate for each indicated condition in NSCLC-SC # 1, NSCLC-SC # 2, NSCLC-SC # 3
and NSCLC-SC # 4. Mean±S.D. of three independent experiments is shown. **P-valueo0.01, ***P-valueo0.001
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51 days post-tumor cells implantation. At the end of the study,
changes in tumor size were not significantly appreciable
(Figure 5b left and right panel), suggesting that the anti-tumor
effects can be protracted after discontinuation of therapy.
The combined treatment with chemotherapy and
AZD7762 prevents tumor growth by targeting NSCLC-
SCs. We next analyzed the type of damage induced by
the different therapeutic regimens on the tumor tissue.
Immunohistochemistry and immunofluorescence analysis of
tumor xenografts explanted at the end of the treatment
showed that only the combination of chemotherapy and
AZD7762 was able to kill extensively tumor cells as indicated
by the increased expression of g-H2A.X and the massive
presence of deoxyuridine triphosphate nick-end labeling
(TUNEL) positive cells, which appeared significantly lower
after the treatment with chemotherapy alone (Figures 6a
and b upper and lower panel, Supplementary Figure S5A
and S5B). Such severe tissue damage was still present
3 weeks after the last delivery of chemotherapy and Chk1
inhibitors, as indicated by the large necrotic areas and rare
cellularity observed in the tumors (Figure 6c left and right
panel and Supplementary Figure S5C). Thus, the thera-
peutic response of chemotherapy and Chk1 inhibitors may
be extended after discontinuation of the treatment.
To investigate whether the combined treatment with
chemotherapy and AZD7762 was able to target NSCLC-
SCs in vivo, we performed a colony-forming assay on cells
derived from dissociation of tumor xenografts, based on the
assumption that the number of clonogenic cells should parallel
the relative number of tumorigenic cells in treated lesions. We
found a significant reduction in the clonogenic ability of cells
derived from co-treated xenografts (Figure 6d, right panel),
whose human origin was proven by HLA staining (Figure 6d,
left panel), confirming that the co-administration of chemo-
therapeutic drugs and Chk1 inhibitors significantly affects the
survival of NSCLC-SCs.
Discussion
The maintenance of genomic stability in normal SCs is
essential to preserve the integrity of cell lineages. Efficient
DNA damage repair and cell cycle control can be maintained
in SCs after oncogenic transformation, as indicated by
glioblastoma SC resistance to IR.13 Here, we show that
NSCLC-SCs are considerably more resistant to chemo-
therapeutic drugs than their differentiated progeny. During
exposure to chemotherapy, NSCLC-SCs undergo a growth
arrest process readily reversible upon drug removal. In the
clinical setting, this behavior could be associated with tumor
Figure 5 Combination of chemotherapy and Chk1 inhibitors strongly affects tumor growth in vivo. (a) Hematoxylin and Eosin (H&E) staining of parental tumor (patient) and
mouse xenograft from NSCLC-SC # 3 and NSCLC-SC # 4. Acquisition was made with a 10 objective. (b) Growth rate of mouse xenografts generated after subcutaneous
injection of NSCLC-SC # 3. Results are mean±S.D. of four independent experiments. Statistical significance at day 30 was tested by means of two-way repeated measures
ANOVA with Bonferroni post-tests (cisplatin versus cisplatinþAZD7762 and gemcitabine versus gemcitabineþ AZD7762). (c) Tumor mass for NSCLC-SC # 3 and NSCLC-
SC # 4 xenografts measured on day 30. Mean±S.D. of three experiments is reported. Five mice for each group were treated with gemcitabine (60 mg/kg), cisplatin (3 mg/kg)
and AZD7762 (10 mg/kg), as indicated, every 3 days from day 0 to day 27. *P-valueo0.05, **Po0.01, ***Po0.001
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recurrence observed in NSCLC patients treated with chemo-
therapy, whose survival is extremely poor. The analysis of
the molecular mechanisms involved in such chemoresistance
showed that upon DNA damage NSCLC-SCs undergo cell
cycle arrest preferentially in S or G2/M phases, thus allowing
DNA repair and successful cell duplication. The checkpoint
kinase Chk1 has a major role in the DNA damage response
and acts as a key regulator of genomic integrity.30 For this
Figure 6 DNA damage, cell death detection and evaluation of clonally expanding NSCLC-SCs in tumor xenografts. (a) Representative immunohistochemistry performed
on formalin-fixed paraffin-embedded tissue for g-H2A.X, indicating an extensive necrotic area at day 30. Acquisitions were made with a 10 and a 40 objective on
NSCLC-SC # 3 xenografts. Lower panel shows the percentage of g-H2A.X-positive cells in NSCLC-SC # 3 and NSCLC-SC # 4 xenografts. (b) Representative Ki67 (green),
Phalloidin (yellow) and TUNEL (red) triple staining acquired with a 40 objective on NSCLC-SC # 3 xenografts sections at day 30. Lower panel shows the percentage of
TUNEL positive cells assessed in three independent experiments performed on NSCLC-SC # 3 and NSCLC-SC # 4 xenografts. (c) Representative H&E performed on frozen
tissue 3 weeks after treatment withdrawal (day 51). Data are representative of three independent experiments performed on mouse xenografts generated after subcutaneous
injection of NSCLC-SC # 3. Right panel shows the percentage of necrotic areas in tumor xenografts of both NSCLC-SC # 3 and NSCLC-SC # 4. Acquisitions were made,
respectively, with a 10 and a 20 objective. (d) Flow cytometry analysis for HLA I and colony-forming ability assay performed on tumor cells obtained from dissociation of
NSCLC-SC # 3 and NSCLC-SC # 4 xenografts (left panel). Average number of colonies/plate for each combination of treatments (right panel). Mean±S.D. of two
independent experiments with 12 wells/condition is reported. **Po0.01, ***Po0.001
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reason Chk1 represents a critical therapeutic target for cancer
treatment.22,23,31–34 Our results show that Chk1 activation is
essential for drug resistance in NSCLC-SCs. Treatment of
NSCLC-SCs with gemcitabine, cisplatin or paclitaxel results in
a strong activation of Chk1, considerably higher than in
differentiated non-tumorigenic cells, indicating that the DNA
damage machinery is more robust in NSCLC-SCs than in their
progeny.
In human cancers, the high p53 mutation rates result in
reliance on S and G2 checkpoints, controlled by Chk1 and
Chk2, to repair DNA damage and promote cell survival. We
observed that Chk1 activation is an early response to DNA
damage even in p53-wild type NSCLC-SCs. After chemo-
therapy treatment in NSCLC-SCs, Chk2 phosphorylation and
p53 activation in p53 proficient cells occurred days after Chk1
activation, suggesting that Chk1 acts as a major DNA damage
checkpoint in NSCLC-SCs, regardless of the p53 status.
Accordingly, we observed that Chk1 inhibitors sensitize
NSCLC-SCs to chemotherapy by altering the DNA damage
response and favoring the incidence of aberrant endomitosis
with subsequent cell death. Our results indicate that the Chk1-
Cdc25-Cdc2-cyclin B1 pathway is efficiently triggered after
drug-induced DNA damage in NSCLC-SCs, as demonstrated
by the ability of Chk1 inhibitors to reduce Cdc25 and Cdc2
phosphorylation and promote cyclin B1 translocation to the
nucleus.
AZD7762 is a new inhibitor of Chk1 and Chk2, currently
in phase I clinical trial in combination with chemotherapy.
This drug has been shown to enhance the response to
chemotherapy and radiotherapy in preclinical models of
colorectal, lung and pancreatic cancer.25,35,36 Unlike cancer
cell lines, CSCs produce tumor xenografts that recapi-
tulate the original tumors and appear a promising tool to
study human tumors and devise more effective therapies.29
Using NSCLC xenografts generated by CSCs, we found that
AZD7762 increases considerably the anti-tumor effect of
chemotherapy.
Compelling evidence indicates tumor regrowth in NSCLC
patients following chemotherapy withdrawal.37–39 We found
that the interruption of co-treatment did not correspond to a
rapid rebound in tumor growth, suggesting that co-adminis-
tration of the Chk1 inhibitor AZD7762 and either gemcitabine
or cisplatin could be exploited to devise more effective
therapeutic approaches for NSCLC. Moreover, the significant
reduction in the number of clonogenic cells in tumor
xenografts treated with the combined therapy suggests that
such treatment affects the survival of NSCLC-SCs, which are
largely spared by chemotherapy alone.
In conclusion, here we show for the first time that primary
NSCLC-SCs survive during the course of chemotherapy by
exploiting an efficient DNA damage response, which can be
prevented by the use of drugs that target Chk1. This
distinctive property, which was not found in differentiated
NSCLC cells, may explain the inefficacy of chemotherapy in
eradicating lung cancer and the consequent poor clinical
outcome of NSCLC patients. Inhibition of Chk1 sensitized
CSCs to chemotherapy-induced DNA damage and dramati-
cally reduced their survival in vitro and in vivo. Together our
results suggest the hypothesis that Chk1 inhibition might
improve the progression-free survival of NSCLC patients
during chemotherapy treatment. Due to the number of Chk1
inhibitors currently undergoing early clinical trials, these
observations argue in favor of a future clinical evaluation of
Chk1 inhibitors in combination with chemotherapy as a
cancer-SC-directed therapy, whereas providing substantial
preclinical support for future phase II clinical trials with the
combination of chemotherapy and Chk1 inhibitors for the
treatment of NSCLC.
Materials and Methods
Cell cultures. Lung cancer specimens were obtained upon informed consent
from patients undergoing surgical resection according to the Institutional Ethical
Committee guidelines on human experimentation and with the Helsinki Declaration.
NSCLC-SCs and differentiated progenies from human adenocarcinoma (NSCLC-SC
# 1 and NSCLC-SC # 4), human squamous cell carcinoma (NSCLC-SC # 2 and
NSCLC-SC # 3) and human large cell neuroendocrine carcinoma (NSCLC-SC # 5),
were obtained from patients who underwent surgical resection of lung tumors and
cultured as previously described.5 Briefly, surgical specimens dissociation was carried
out by enzymatic digestion (20 mg/ml collagenase II, Gibco-Invitrogen, Carlsbad, CA,
USA) for 2 h at 37 1C. Recovered cells were cultured at clonal density in serum-free
medium supplemented with 20 mg/ml epidermal growth factor (EGF) and 10 mg/ml
basic fibroblast growth factor (b-FGF). Flasks non-treated for tissue culture were used to
reduce cell adherence and support growth as undifferentiated tumor spheres. The
medium was replaced or supplemented with fresh growth factors twice a week until cells
started to grow forming floating aggregates. Cultures were expanded by mechanical
dissociation of spheres, followed by re-plating of both single cells and residual small
aggregates in complete fresh medium. To obtain differentiation of lung cancer sphere-
forming cells, stem cell medium was replaced for 3 days with Bronchial Epithelial Cell
Growth Medium (Cambrex, East Rutherford, NJ, USA) in tissue culture-treated flasks, to
allow cell attachment and differentiation. Adherent cells were thereafter grown in DMEM
supplemented with 10% serum. The acquisition of differentiation markers was evaluated
by immunofluorescence.
Molecular analysis. Mutational screening was performed on the coding exons
1 and 2 of KRAS, exons 5 to 8 of TP53 and the EGFR cDNA portion coding for the
N-terminal region of the tyrosine kinase domain (residues 711–863). Genomic DNA
specimens were obtained from NSCLC-SCs using PureLinkTM Genomic DNA
Purification Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
protocols. Total RNA was extracted from NSCLC-SCs using the RNeasy mini kit
(Qiagen, Hilden, Germany). RNA (1mg) was reverse transcribed into cDNA by using
SuperScript II RT with oligo(dT) as primers (Invitrogen) according to the
manufacturer’s protocol. PCR amplifications were carried out using high-fidelity
Optimase polymerase (Transgenomic, Omaha, NE, USA). Primer pairs and PCR
conditions are listed in Supplementary Methods Table 1. Unpurified PCR products
were analyzed by denaturing high-performance liquid chromatography (DHPLC)
with the Wave 2100 DNA fragment analysis system (Transgenomic) at column
temperatures recommended by Navigator software, version 1.6.4.12
(Transgenomic). Heterozygous templates with previously identified mutations or
single nucleotide polymorphisms were used as positive controls in each DHPLC run.
DHPLC analysis of pooled DNAs was performed to explore possible occurrence of
homozygous/hemizygous condition for mutations. Amplimers with abnormal
denaturing profiles were re-amplified, purified (Microcon PCR; Millipore, Bedford,
MA, USA) and sequenced bidirectionally using the ABI BigDye Terminator
Sequencing Kit v.1.1 (Applied Biosystems, Carlsbad, CA, USA) and an ABI Prism
310 Genetic Analyzer (Applied Biosystems).
Reagents. Cisplatin was purchased from Teva (Petach Tikva, Israel),
gemcitabine from Lilly (Indianapolis, IN, USA), paclitaxel from Sigma-Aldrich
(St. Louis, MO, USA), SB218078 from Calbiochem (Nottingham, UK) and AZD7762
from Axon Medchem (Groningen, The Netherlands).
Treatments. For in vitro experiments the following compounds were used:
cisplatin (5 mg/ml), gemcitabine (50mM), paclitaxel (30 ng/ml), SB218078 (20 nM)
and AZD7762 (5 nM). For in vivo studies we used: gemcitabine (60 mg/kg), cisplatin
(3 mg/kg) and AZD7762 (10 mg/kg). Chk1 inhibitors were added 8 h after
chemotherapy for both in vitro and in vivo studies.
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Cell viability assays. For chemoresistance comparison and cell viability
studies, dissociated spheres and adherent differentiated cells were plated in 96 well
plates at 5000 cells/well in growth medium supplemented with cisplatin, gemcitabine
or paclitaxel, for 96 h. For cell viability studies, dissociated NSCLC-SCs were
seeded and treated as described above and in combination with Chk1 inhibitors.
Cell viability was evaluated after 96 h by CellTiter-Glo Luminescent Cell Viability
Assay (Promega, Madison, WI, USA) according to standard protocols and analyzed
with a Victor 2 plate reader (Wallac, Turku, Finland).
Cell proliferation assays. Dissociated NSCLC-SCs were treated with
cisplatin, gemcitabine or paclitaxel for 6 days. On day 3 cells were collected,
counted by Trypan Blue exclusion and replated in the presence of chemotherapy.
On day 6 cells were collected, counted by Trypan Blue exclusion and replated in
fresh medium without chemotherapy. Thereafter, cells were counted and replated
every 3 days until day 15.
Cell cycle analysis. NSCLC-SCs were dissociated and treated with cisplatin,
gemcitabine or paclitaxel. After 48 h, cells were stained with a propidium iodide (PI)
staining solution (trisodium citrate 0.1%, NaCl 9.65 mM, NP40 0.3%, PI 50 mg/ml
and RNase A 200mg/ml) for 30 min at RT. Cell cycle profile was acquired with a
FACSCanto flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and
analyzed with FlowJo software (Tree Star Inc.; http://www.flowjo.com/index.php).
Western blot. NSCLC-SCs were treated for 6 h, 12 h, 24 h or 96 h as previously
described. Whole-cell lysates (20 mg) were fractioned on SDS-polyacrylamide gels,
blotted to nitrocellulose membranes and incubated with the following antibodies:
Chk1, phosphorylated Chk1 (Ser345), Chk2 (1C12), phosphorylated Chk2 (Thr68),
phosphorylated Cdc25C (Ser216) and phosphorylated Cdc2 (Tyr15) from Cell
Signaling Technology (Danvers, MA, USA); ATM (5C2), phosphorylated ATM
(0H11.E12) and cyclin B1 (clone D-11) from Santa Cruz Biotechnology (Santa Cruz,
CA, USA); phosphorylated H2A.X (Ser139) (g-H2A.X) from Upstate-Millipore
(Billerica, MA, USA), b-actin (AC-15) and b-tubulin (TUB 2.1) from Sigma-Aldrich,
and detected using enhanced chemiluminescence detection kit (Pierce, Rockford,
IL, USA). Densitometric analysis was performed using Scion Image (Scion
Corporation, Frederick, MO, USA) and all results were normalized over b-actin or
b-tubulin (ATM and p-ATM).
Immunofluorescence. Cells were treated with cisplatin, paclitaxel,
SB218078 or AZD7762 alone or in combinations for 48 or 96 h. For cyclin B1
staining, treated cells were fixed with 2% paraformaldehyde and then perme-
abilized with 0.1% Triton X-100/PBS for 1 h at 37 1C before incubation with
cyclin B1 (clone D-11, Santa Cruz Biotechnology) overnight at 4 1C. Thereafter,
slides were incubated with Alexa Fluor 488 goat anti-mouse (1 mg/ml, Invitrogen)
for 1 h at RT. TO-PRO-3 (4 mM, Invitrogen) and Phalloidin-AlexaFluor 488
(5Units/ml, Molecular Probes/Invitrogen) were used to visualize nuclei and F-actin
cytoskeleton. For tumor xenografts immunofluorescence, resected tumors were
fixed with 10% (vol/vol) formalin (BioOptica, Milan, Italy) for 24 h and subse-
quently passed from 10% to 30% concentrations of sucrose. Tumors were
mounted in Killik frozen section medium (BioOptica) and 5 mm-thick sections were
cut and incubated with terminal deoxynucleotidyl transferase-mediated TUNEL
reaction mixture (Roche, Basel, Switzerland) for 1 h at RT followed by anti-Ki67
(DAKO, Glostrup, Denmark) overnight at 4 1C. AlexaFluor 555-conjugated goat
anti-mouse secondary antibody (1mg/ml, Invitrogen) was incubated for 1 h at RT.
Nuclei and cytoskeleton were counterstained using DAPI and Alexa Fluor 647-
conjugated Phalloidin (Invitrogen), respectively. Slides were subsequently mounted
using an anti-fade mounting medium (Invitrogen) and analyzed using an
Olympus FV-1000 spectral confocal microscope equipped with an UltraPlan
Apochromatic 60 NA 1.35 and an UltraPlan Fluorite 40 NA 1.3 objectives and
the software Olympus Fluoview (Olympus, Tokyo, Japan). To evaluate the
percentage of TUNEL positive cells in tumor xenografts, image analysis was
performed with ImageJ (http://rsb.info.nih.gov/ij/). Single channels were extracted
from the confocal images either for nuclei (DAPI) or for TUNEL (TMR-Red), and
after application of a threshold that eliminates background dust, a watershed filter
was applied on the binary images. The tool for particle analysis was used to
quantify the amount of TUNEL positivity as compared with the number of
DAPI-stained nuclei/particles.
Colony-forming ability assay. Soft agar colony-forming assays were
carried out for NSCLC-SCs treated with cisplatin or paclitaxel either alone or in
combination with SB218078 or AZD7762 for 96 h. Subsequently, cells were washed
and 500 single cells were plated in the top agar layer in each well of a 24-well culture
plate with 0.3% top agar layer and 0.4% bottom agar layer (SeaPlaque Agarose,
Cambrex, NJ, USA). Cultures were incubated at 37 1C for 20 days. Colonies from
triplicate wells were stained with crystal violet (0.01% in 10% MetOH), visualized
and counted under microscope and photographed. To evaluate the colony-forming
ability of freshly isolated cancer cells, human tumors were obtained from four
NSCLC patients who underwent surgical resection and dissociated as previously
described.5 In order to eliminate contaminating non-tumoral cells, recovered cells
were stained with FITC-conjugated epithelial cell adhesion molecule (EpCAM)
(DakoCytomation, Glostrup, Denmark) and sorted with a FACS Aria (Becton
Dickinson). Thereafter, cells were treated with gemcitabine and cisplatin alone or in
combination with AZD7762 for 96 h, extensively washed and plated at 500 cells/
well, using 24 wells for each condition. After 50 days, colonies were stained,
visualized and counted under the microscope. To obtain xenograft-derived cells,
tumors were aseptically removed and dissociated. Cells recovered were extensively
washed, plated in stem cell medium for 4 days and subsequently 500 cells for each
treatment condition were plated as described above. After 20 days, colonies were
visualized and counted as described above.
In vivo studies. Five-week-old female NOD-SCID mice from Charles River
Laboratories (Wilmington, MA, USA) were maintained in accordance with the
institutional guidelines of the Istituto Superiore di Sanita` Animal Care Committee.
NSCLC-SCs were dissociated, counted and resuspended in a mix of PBS and
Matrigel (1 : 1). To obtain synchronized tumors in about 4 weeks, 50 000 NSCLC-
SCs were injected subcutaneously into the right flank of each mouse. Tumors were
allowed to grow to the size ofB0.3 cm3 before the administration of compounds.
Mice were treated intraperitoneally with either gemcitabine (60 mg/kg) or cisplatin
(3 mg/kg), and intravenously with AZD7762 (10 mg/kg) every 3 days. Tumor growth
was evaluated with an electronic caliper before every administration. After 30 days,
tumors were removed and weighed using a PL202-L Precision Balance (Mettler-
Toledo, Novate Milanese, Italy). To evaluate drugs combination efficacy, tumors
were allowed to grow in the absence of treatment and measured every 3 days until
day 51. Immunohistochemistry was performed on formalin-fixed paraffin-embedded
tissues or frozen tissues. Paraffin sections (5 mm) were dewaxed in xylene and
rehydrated with distilled water and subsequently incubated with anti-g-H2A.X
(Upstate-Millipore). The reaction was performed using Elite Vector Stain ABC
systems (Vector Laboratories, Burlingame, CA, USA) and DAB substrate
chromogen (DakoCytomation), followed by counterstaining with haematoxylin.
H&E staining was performed on 5mm frozen sections and observed through
a Nikon Eclipse E1000 transmitted light right microscope equipped with
PlanFluor 10 and 20 dry objectives (Nikon, Melville, NY, USA). Images
were subsequently taken by using a Nikon DXM1200 RGB camera and the
Nikon ACT-1 software. Percentage of g-H2A.X-positive cells in tumor xenografts
was assessed by counting five different fields in each slide derived from two
independent experiments. Percentage of necrotic areas was evaluated by
comparing in each slide the number of pixels included in necrotic versus
viable areas. Image analysis was performed with ImageJ (http://rsb.info.nih.gov/ij/).
Human origin of the tumor xenografts was confirmed by FACS analysis with a PE
conjugated anti-HLA class I antibody (eBioscience, San Diego, CA, USA), whereas
a PE-Cy5 anti-mouse CD45 antibody (BD Pharmingen, San Diego, CA, USA) was
used to exclude unspecific staining of mouse cells.
Statistical analysis. All statistical analyses were performed using GraphPad
Prism 4 (GraphPad Software Inc., http://www.graphpad.com/welcome.htm). Data
are presented as mean±standard deviation (S.D.). Statistical significance was
determined by ANOVA (one-way or two-way) with Bonferroni post-test. A P value
o0.05 is represented by a single asterisk, a P value o0.01 is represented by a
double asterisk, whereas three asterisks indicate Po0.001.
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